Aeterna Zentaris Inc. (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 16,900 shares, a decrease of 22.1% from the March 31st total of 21,700 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average daily volume of 15,900 shares, the short-interest ratio is presently 1.1 days.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on Aeterna Zentaris in a report on Monday, April 22nd. They set a “sell” rating for the company.
Check Out Our Latest Research Report on Aeterna Zentaris
Aeterna Zentaris Stock Performance
Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last released its quarterly earnings data on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.19). The company had revenue of $0.12 million for the quarter. Aeterna Zentaris had a negative net margin of 368.01% and a negative return on equity of 63.20%.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.
Further Reading
- Five stocks we like better than Aeterna Zentaris
- Best Stocks Under $5.00
- MarketBeat Week in Review – 4/22 – 4/26
- Using the MarketBeat Stock Split Calculator
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Find Undervalued Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.